T. Rowe Price Associates
ATNM icon

T. Rowe Price Associates’s Actinium Pharmaceuticals ATNM Stock Holding History

T. Rowe Price Associates’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,785
Closed -$21K – 3066
2025
Q1 		$21K Buy
+12,785
New +$16.2K ﹤0.01% 3003

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

T. Rowe Price Associates's ATNM Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 12,785 shares — an estimated $21K sold.

T. Rowe Price Associates first reported a position in ATNM in Q1 2025 and held it in 1 quarter. The position peaked at $21K in Q1 2025. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 12,785 Actinium Pharmaceuticals shares in Q2 2025, an estimated $21K.
  • T. Rowe Price Associates first reported a position in Actinium Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • T. Rowe Price Associates's Actinium Pharmaceuticals position peaked at $21K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.